drug
DAPAGLIFLOZIN
Marketedupdated 5mo agoby Lupin Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval78 co-mentions · 27 sources
- drugDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE65 co-mentions · 29 sources
- drugDAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE65 co-mentions · 29 sources
- tagSmall Molecule37 co-mentions · 26 sources
- drugmetformin22 co-mentions · 10 sources
- drugSITAGLIPTIN AND METFORMIN HYDROCHLORIDE22 co-mentions · 10 sources
- drugmetformin hydrochloride22 co-mentions · 10 sources
- drugmetformin hydrochloride ER22 co-mentions · 10 sources
indications
investigational
Type 2 Diabetes
all catalysts(21)
approval · 20
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Trials studying DAPAGLIFLOZIN
- N/AThe DAPA-MEMRI Trial
- phase2A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
- phase3Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
- phase3A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
- phase3A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- phase4Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
- phase4The Fontan Dapagliflozin Pilot Study
- phase3A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 20, 2027
252 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (64)
- May 12, 2031patentUS 9616028*PED4.6y
- May 12, 2031patentUS 9616028*PED4.6y
- May 12, 2031patentUS 9616028*PED4.6y
- May 12, 2031patentUS 9616028*PED4.6y
- Nov 12, 2030formulationUS 96160284.1y
- Nov 12, 2030formulationUS 96160284.1y
- Nov 12, 2030formulationUS 96160284.1y
- Nov 12, 2030formulationUS 96160284.1y
- Jun 16, 2030patentUS 7919598*PED3.7y
- Jun 16, 2030patentUS 7919598*PED3.7y
- Jun 16, 2030patentUS 7919598*PED3.7y
- Jun 16, 2030patentUS 7919598*PED3.7y
- Jun 16, 2030patentUS 7919598*PED3.7y
- Jun 16, 2030patentUS 7919598*PED3.7y
- Dec 16, 2029compositionUS 79195983.2y
- Dec 16, 2029compositionUS 79195983.2y
- Dec 16, 2029compositionUS 79195983.2y
- Dec 16, 2029compositionUS 79195983.2y
- Dec 16, 2029compositionUS 79195983.2y
- Dec 16, 2029compositionUS 79195983.2y
- Sep 21, 2028patentUS 8221786*PED1.9y
- Sep 21, 2028patentUS 8221786*PED1.9y
- Sep 21, 2028patentUS 8361972*PED1.9y
- Sep 21, 2028patentUS 8361972*PED1.9y
- Sep 21, 2028patentUS 8716251*PED1.9y
- Sep 21, 2028patentUS 8716251*PED1.9y
- Sep 21, 2028patentUS 8716251*PED1.9y
- Sep 21, 2028patentUS 8716251*PED1.9y
- Sep 21, 2028patentUS 8716251*PED1.9y
- Sep 21, 2028patentUS 8716251*PED1.9y
- Mar 21, 2028formulationUS 82217861.4y
- Mar 21, 2028formulationUS 82217861.4y
- Mar 21, 2028method-of-use (U-493)US 83619721.4y
- Mar 21, 2028method-of-use (U-493)US 83619721.4y
- Mar 21, 2028formulationUS 87162511.4y
- Mar 21, 2028formulationUS 87162511.4y
- Mar 21, 2028formulationUS 87162511.4y
- Mar 21, 2028formulationUS 87162511.4y
- Mar 21, 2028formulationUS 87162511.4y
- Mar 21, 2028formulationUS 87162511.4y
- Dec 20, 2027patentUS 8501698*PED1.2y
- Dec 20, 2027patentUS 8501698*PED1.2y
- Dec 20, 2027patentUS 8501698*PED1.2y
- Dec 20, 2027patentUS 8501698*PED1.2y
- Dec 20, 2027patentUS 8501698*PED1.2y
- Dec 20, 2027patentUS 8501698*PED1.2y
- Jun 20, 2027formulationUS 8501698252d
- Jun 20, 2027formulationUS 8501698252d
- Jun 20, 2027formulationUS 8501698252d
- Jun 20, 2027formulationUS 8501698252d
- Jun 20, 2027formulationUS 8501698252d
- Jun 20, 2027formulationUS 8501698252d
- Apr 4, 2026patentUS 6515117*PED
- Apr 4, 2026patentUS 6515117*PED
- Apr 4, 2026patentUS 6515117*PED
- Apr 4, 2026patentUS 6515117*PED
- Apr 4, 2026patentUS 6515117*PED
- Apr 4, 2026patentUS 6515117*PED
- Oct 4, 2025compositionUS 6515117
- Oct 4, 2025compositionUS 6515117
- Oct 4, 2025compositionUS 6515117
- Oct 4, 2025compositionUS 6515117
- Oct 4, 2025compositionUS 6515117
- Oct 4, 2025compositionUS 6515117
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that